CHRS — Coherus Oncology Cashflow Statement
0.000.00%
Last trade - 00:00- $191.78m
- $4.11m
- $266.96m
- 73
- 42
- 70
- 67
Annual cashflow statement for Coherus Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 132 | -287 | -292 | -238 | 28.5 |
| Depreciation | |||||
| Non-Cash Items | 51.1 | 203 | 126 | 96 | -110 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -32.1 | 42.9 | -79.3 | -36.8 | 55.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 154 | -37.4 | -241 | -175 | -20.4 |
| Capital Expenditures | -7.23 | -1.29 | -2.04 | -0.286 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -7.17 | -137 | -165 | 145 | 230 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -14.4 | -138 | -167 | 145 | 230 |
| Financing Cash Flow Items | -0.88 | -1.75 | -4.97 | -4.62 | 33.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 224 | 51.9 | 54.3 | 69.6 | -187 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 364 | -124 | -354 | 39.4 | 22.9 |